While the idea of adding costs to a food and beverage or pharmaceutical industry process like Clean-in-Place/Steam-in-Place (CIP/SIP) has not traditionally been an easy decision, in today’s industrial environment that has changed. With the retirement of experts, the...
Pollutants are produced by industrial emissions, automobile exhaust, and household waste. As well as chemical gases such as NOx, fluorocarbons are also present. With CO2 and methane, they cause acid rain, sick house syndrome, depletion of the ozone layer, and, of course, climate change.
The life sciences marketplace is changing faster than nearly any other industry. Gone are the days when companies focus on a single treatment to drive their entire business. Today’s life sciences manufacturers are challenged to bring new treatments to the marketplace...
Christian Berg describes some solutions and technologies which facilitate the pursuit of the adaptive plant for manufacturers in the Life Sciences industry, as defined by the BioPhorum Digital Plant Maturity Model.
In a Pharma Focus Asia webinar, Pursuing the Adaptive Plant to Enable Personalized Healthcare, Emerson’s Christian Berg provides a broader perspective of personalized healthcare and its challenges for the Life Sciences industry.
Sean Buckley and co-authors from Roche, Takeda, and BioPhorum author CGT [cell & gene therapy] Actors and Process Maps which highlight six common types of CGT showing how the pattern of actors and process blocks varies by therapy type.
The BioPhorum Operations Group (BPOG) established a digital plant maturity model (DPMM) for biopharmaceutical manufacturing to define stages of factory evolution “from simple paper-based plants through to the fully automated and integrated ‘adaptive plant’ of the future.” The model gives organizations a common tool for industry comparison and measurement of progress. It also provides a platform to facilitate collaboration within the life sciences industry and its technology providers.
Traditional manufacturing practices have served the biopharmaceutical industry well for years, but times are changing and a need for speed to market in life sciences while reducing manufacturing costs is putting a focus on enabling real-time release (RTR)....
The BioPhorum CGT Personas and User Stories toolkit details the needs of all the key players involved in end-to-end cell and gene therapy (CGT) processes. It can be used by anyone who wishes to better understand how IT systems can support the manufacture and delivery of CGTs.
One of the key stages delaying and increasing costs in life sciences projects is equipment validation. In fact, it is one of the elements of project completion that project teams are most eager to compress because the value of every incremental improvement is so...
For biotech industries, Emerson offers fundamental automation solutions with quicker uptimes and more consistent batch quality.
In BioPhorum’s MES of the Future Manifesto, Sean and Kate Porter collaborated with other biomanufacturing leaders on requirements for future Manufacturing Execution Systems.
We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to stay up to date on the latest news, events and innovations that will help you face and solve your toughest challenges.
Just post a link to the entry and send us a quick note so we can share your work. Thank you very much.
Our Global Community
Emerson Exchange 365
The opinions expressed here are the personal opinions of the authors. Content published here is not read or approved by Emerson before it is posted and does not necessarily represent the views and opinions of Emerson.